The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.

Original title: “Bristol Myers deepens AI investment with Anthropic deal”

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.

Original title: “Oorja, run by Acceleron veterans, launches to make new fibrosis drugs”

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

Original title: “Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update”

FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesday.

Original title: “Pazdur declines to announce candidacy for vacated FDA commissioner role”

While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.

Original title: “Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform”

Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma’s top paid CEOs make up to 358 times more than their employees; Revolution Medicine’s pancreatic cancer results highlight movement in the deadly disease space; more.

Original title: “FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum”

Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo's ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.

Original title: “Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues”

BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.

Original title: “J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times”

Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.

Original title: “BioMarin drug acquired in buyout misses goal in rare disease study”

Far fewer companies are letting employees go so far in 2026 compared to 2025, but the number of people affected is trending up, especially this month, according to BioSpace tallies.

Original title: “Takeda cuts send layoffs soaring in May, rising year over year”

Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a discovery system built around scientific uncertainty. Structural changes are needed to sustain the sector’s strategic innovation.

Original title: “Biotech can’t continue to innovate under strain of Big Pharma market pressures”